R
Raymond C. Read
Researcher at University of Arkansas for Medical Sciences
Publications - 152
Citations - 6007
Raymond C. Read is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Hernia & Rectus sheath. The author has an hindex of 40, co-authored 152 publications receiving 5873 citations. Previous affiliations of Raymond C. Read include University of Arkansas & John L. Scott.
Papers
More filters
Journal ArticleDOI
Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study.
Steve Goldman,Jack G. Copeland,T Moritz,William G. Henderson,K Zadina,T Ovitt,James E. Doherty,Raymond C. Read,Elliot Chesler,Y Sako +9 more
TL;DR: In this article, the authors compared aspirin, 325 mg daily, aspirin and dipyridamole (DMD), and sulfinpyrazone (267 mg three times daily), and placebo (three times daily).
Journal ArticleDOI
Systemic effects of smoking
TL;DR: Evidence indicates that nicotine releases endorphins, which account for the addiction, and surgeons need to do more to combat this menace.
Journal ArticleDOI
Recent Trends in the Management of Incisional Herniation
Raymond C. Read,Gordon Yoder +1 more
TL;DR: There is a high incidence of risk factors for incisional herniation in hospitalized veterans and "Buttonholing" of the rectus sheath by a sawing motion of the continuous nonabsorbable suture may be responsible for this later herniated.
Journal ArticleDOI
Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study.
Steve Goldman,Jack G. Copeland,T Moritz,William G. Henderson,K Zadina,T Ovitt,James E. Doherty,Raymond C. Read,Elliot Chesler,Y Sako +9 more
TL;DR: To determine whether antiplatelet therapies improve saphenous vein graft patency after coronary artery bypass grafting, they were compared with aspirin (325 mg once daily), dipyridamole and sulfinpyrazone (267 mg three times daily), and placebo (three times daily).
Journal ArticleDOI
Second primary lung cancer
TL;DR: There was no evidence that minimal resection for the first primary tumor predisposed to SPLC, and survival rates at 3 and 5 years were 26% and 18%, metachronous 39% and 23.4%, and synchronous 12.25% and 12.5%.